Fasudil hydrochloride induces osteoblastic differentiation of stromal cell lines, C3H10T1/2 and ST2, via bone morphogenetic protein-2 expression

Endocrine Journal

Volumn 57, Issue 5, 2010, Pages 415-421

  Kanazawa, Ippei ^a   Yamaguchi, Toru ^a   Yano, Shozo ^a   Yamauchi, Mika ^a   Sugimoto, Toshitsugu ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

BMP 2; Bone formation; Fasudil; Rho kinase; Stromal cell

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; COLLAGEN TYPE 1; FASUDIL; MESSENGER RNA; NOGGIN; OSTEOCALCIN;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; DRUG EFFECT; ENZYME ACTIVITY; MINERALIZATION; NONHUMAN; OSTEOBLAST; PROTEIN EXPRESSION; STROMA CELL;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; BONE MORPHOGENETIC PROTEIN 2; CALCIFICATION, PHYSIOLOGIC; CARRIER PROTEINS; CELL DIFFERENTIATION; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION; MICE; OSTEOBLASTS; OSTEOGENESIS; PROTEIN KINASE INHIBITORS; STROMAL CELLS;

EID: 77953641485     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K09E-328     Document Type: Article

References (33)

1. Shimokawa H (2002) Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol 39: 319-327.
2. Shimokawa H, Hiramori K, Iimura H, Hosoda S, Kishida H, Osada H, Katagiri T, Yamauchi K, Yui Y, Minamino T, Nakashima M, Kato K (2002) Antianginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol 40: 751-761.
3. Loirand G, Guerin P, Pacaud P (2006) Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 98: 322-334.
4. Shimokawa H, Takeshita A (2005) Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25: 1767-1775.
5. Ohnaka K, Shimoda S, Nawata H, Shimokawa H, Kaibuchi K, Iwamoto Y, Takayanagi R (2001) Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Commun 287: 337-342.
6. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T (2009) Activation of AMP-kinase and inhibition of Rho-kinase induce the mineralization of osteoblastic MC3T3-E1 cells through endothelial NOS and BMP-2 expression. Am J Physiol Endocrinol Metab 296: E139-146.
7. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T (2007) Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells. BMC Cell Biol 8: 51.
8. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T (2008) Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun 375: 414-419.
9. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408.
10. Lowry OH, Roberts NR, Wu ML, Hixon WS, Crawford EJ (1954) The quantitative histochemistry of brain. II. Enzyme measurements. J Biol Chem 207: 19-37.
11. Miyata K, Shimokawa H, Kandabashi T, Higo T, Morishige K, Eto Y, Egashira K, Kaibuchi K, Takeshita A (2000) Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo. Arterioscler Thromb Vasc Biol 20: 2351-2358.
12. Sawada N, Itoh H, Ueyama K, Yamashita J, Doi K, Chun TH, Inoue M, Masatsugu K, Saito T, Fukunaga Y, Sakaguchi S, Arai H, Ohno N, Komeda M, Nakao K (2000) Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation 101: 2030-2033.
13. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S (1997) Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389: 990-994.
14. Sandu OA, Ragolia L, Begum N (2000) Diabetes in the Goto-Kakizaki rat is accompanied by impaired insulinmediated myosin-bound phosphatase activation and vascular smooth muscle cell relaxation. Diabetes 49: 2178-2189.
15. Essler M, Retzer M, Bauer M, Heemskerk JW, Aepfelbacher M, Siess W (1999) Mildly oxidized low density lipoprotein induces contraction of human endothelial cells through activation of Rho/Rho kinase and inhibition of myosin light chain phosphatase. J Biol Chem 274: 30361-30364.
16. Rikitake Y, Liao JK (2005) Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-I expression in vascular endothelial cells. Circulation 111: 3261-3268.
17. Hiroki J, Shimokawa H, Mukai Y, Ichiki T, Takeshita A (2005) Divergent effects of estrogen and nicotine on Rho-kinase expression in human coronary vascular smooth muscle cells. Biochem Biophys Res Commun 326: 154-159.
18. Harmey D, Stenbeck G, Nobes CD, Lax AJ, Grigoriadis AE (2004) Regulation of osteoblast differentiation by Pasteurella multocida toxin (PMT): a role for Rho GTPase in bone formation. J Bone Miner Res 19: 661-670.
19. Meyers VE, Zayzafoon M, Douglas JT, McDonald JM (2005) RhoA and cytoskeletal disruption mediate reduced osteoblastogenesis and enhanced adipogenesis of human mesenchymal stem cells in modeled microgravity. J Bone Miner Res 20: 1858-1866.
20. Liu Y, Ren W, Warburton R, Toksoz D, Fanburg BL (2009) Serotonin induces Rho/ROCK-dependent activation of Smads 1/5/8 in pulmonary artery smooth muscle cells. FASEB J 23: 2299-2306.
21. Reddi AH (1994) Bone and cartilage differentiation. Curr Opin Genet Dev 4: 737-744.
22. Dhosh-Choudhury N, Harris MA, Feng JQ, Mundy GR, Harris SE (1994) Expression of the BMP 2 gene during bone cell differentiation. Crit Rev Eukaryot Gene Expr 4: 345-355.
23. Sakou T (1998) Bone morphogenetic proteins: from basic studies to clinical approaches. Bone 22: 591-603.
24. Karsenty G (2000) Role of Cbfa1 in osteoblast differentiation and function. Semin Cell Dev Biol 11, 343-346.
25. Ducy P, Schinke T, Karsenty G (2000) The osteoblast: a sophisticated fibroblast under central surveillance. Science 289: 1501-1504.
26. McFarlane SI, Muniyappa R, Shin JJ, Bathtiyar G, Sowers JR (2004) Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine 23: 1-10.
27. Browner WS, Pressman AR, Nevitt MC, Cauley JA, Cummings SR (1993) Association between low bone density and stroke in elderly women. Stroke 24: 940-946.
28. Tanko LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR (2005) Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 20: 1912-1920.
29. Vogt MT, San Valentin R, Forrest KY, Nevitt MC, Cauley JA (1997) Bone mineral density and aortic calcification: the Study of Osteoporotic Fractures. J Am Geriatr Soc 45: 140-145.
30. von der Recke P, Hansen MA, Hassager C (1999) The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 106: 273-278.
31. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK (2002) Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 106: 57-62.
32. Laufs U, Liao JK (2000) Targeting Rho in cardiovascular disease. Circ Res 87, 526-528.
33. Laufs U, Liao JK (1998) Post-transcriptional regulation of endothelial nitric oxide syntase mRNA stability by Rho GTPase. J Biol Chem 273: 24266-24271.